Additionally, the IL-1 (Anakinra) [23], and the IL-6 (Tocilizumab) [24] receptor blockers showed a significant improvement in COVID-19-infected individuals, which supports the COVID-19 "cytokine storm" response theory. Here, IL6 is linked to COVID-19.